Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
Brief pharmaceutical news items for February 2008.

Pharmaceutical Technology


Expansions

Gibraltar Adds Testing Capacity

Gibraltar Laboratories (Fairfield, NJ) is adding 16,000 ft2 of space to its newly-acquired facility in Fairfield. The space will comply with current good manufacturing practices. Together with the current 10,000-ft2 laboratory and office complex, the acquisition will buttress the company's ability to provide microbiology and analytical-chemistry testing to its pharmaceutical and biotechnology clients.

The new facility will include a Class-100 sterility-test suite, Class-1000 staging and gowning areas, and a walk-in incubator A laboratory will be dedicated to microbial-control and decontamination research.

Bilcare Inaugurates Centre of Excellence

Dr. A.P.J. Abdul Kalam, former president of India, and Dr. John L. LaMattina, senior vice-president of Pfizer, inaugurated Bilcare's (Pune, India) Centre of Excellence in Pune. The Centre has dedicated sections for packaging research, material research, analytical research, drug sensitivity studies, and package design. Dr. R. Chidambaram, principal scientific advisor to the government of India, opened the Centre's state-of-the-art pilot plant.

Azopharma Opens Analytical Laboratories Facility

Azopharma (Miramar, FL) opened a new Cyanta Analytical Laboratories facility in Maryland Heights, Missouri. The new 20,000-ft2 modern laboratory is equipped with state-of-the-art instrumentation to support pharmaceutical and medical-device product development. The site is specifically designed to aid analytical method development and inhalation and respiratory services. The new facilities have been modified and updated to meet the demands of Azopharma's pharmaceutical, medical-device, and biotechnology customers.

Millipore Launches UHPLC Sample Prep Website

Millipore (Billerica, MA), a company that provides services for the bioscience research and biopharmaceutical manufacturing industries, launched a website ( http://www.millipore.com/prep4UHPLC/) for the preparation of samples and solutions used in ultrahigh-performance liquid chromatography (UHPLC).

The website offers technical information about Millipore's "UHPLC Compatible" sample-preparation products. The site also includes a product catalog, a support center, and facilitates product ordering and tracking. In addition, the site features Millipore's brochure titled "Maximize the Performance of Your UHPLC System."

People

DIA Names Female Executive Director

The Drug Information Association (DIA, Horsham, PA) appointed Linda McGoldrick its new worldwide executive director. She is the first woman to serve in that role.

In her new position, McGoldrick will direct the association's global operations, expand its presence in strategic locations around the world, and lead the implementation of DIA's strategic plan. McGoldrick plans to establish a foothold in several markets such as India, China, Eastern Europe, and Latin America. McGoldrick replaces William Brassington, who served as acting executive director beginning in 2006.

Microfluidics Appoints CEO

Microfluidics (Newton, MA) appointed Michael C. Ferrara as its new chief executive officer. Ferrara will be responsible for overseeing daily company operations and will serve on the Microfluidics board of directors.


Michael C. Ferrara
Ferrara was most recently president and CEO of X-Rite (Grand Rapids, MI), a color-management company. Under Ferrara's leadership, X-Rite achieved record revenues. In addition, Ferrara has extensive experience in building marketing and distribution channels with strategic partners in Asia–Pacific and Europe. These are areas that Microfluidics intends to focus on in the future.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here